Carlsmed, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The awards vest over multiple years, with vesting conditional on each executive’s continued service.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Carlsmed (CARL) granted equity awards to its newly hired Chief Financial Officer and Chief Product and AI Officer as employment inducements.
On September 28, 2026, Chief Financial Officer Richard Heppenstall received options to purchase 180,137 shares and 89,286 time-based restricted stock units (RSUs). On October 1, 2026, Chief Product and AI Officer Anthony Jarc received options to purchase 132,464 shares and 63,735 time-based RSUs. The options' exercise prices equal the shares' fair market value on each respective grant date. The independent-director Compensation Committee approved the awards outside the equity incentive plan under Nasdaq Listing Rule 5635(c)(4).
Positive
- None.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Heppenstall's 180,137 stock options and 89,286 RSUs create potential dilution, subject to vesting and option exercise.
- Minor point. Forward-looking: it has not happened yet and may not happen.Jarc's 132,464 stock options and 63,735 RSUs create potential dilution, subject to vesting and option exercise.
News Explained
Carlsmed’s granted options vest subject to continued service, with 25% after one year and the remainder in 12 quarterly installments; its RSUs vest in three equal annual installments from the first anniversary, also subject to service, so vesting is staged rather than immediate.
Key Figures
- CFO stock options
- 180,137 shares
- Granted September 28, 2026, as an inducement to employment
- CFO RSUs
- 89,286 RSUs
- Granted September 28, 2026, as an inducement to employment
- Chief Product and AI Officer stock options
- 132,464 shares
- Granted October 1, 2026, as an inducement to employment
- Chief Product and AI Officer RSUs
- 63,735 RSUs
- Granted October 1, 2026, as an inducement to employment
Key Terms
restricted stock units financial
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
CARLSBAD, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that on September 28, 2026, it granted stock options to purchase 180,137 shares of the Company’s common stock and 89,286 time-based restricted stock units (“RSUs”) to Richard Heppenstall, the Company’s newly-hired Chief Financial Officer, as a material inducement to his employment.
The Company further announced that on October 1, 2026, it granted stock options to purchase 132,464 shares of the Company’s common stock and 63,735 time-based RSUs to Anthony Jarc, the Company’s newly-hired Chief Product and AI Officer, as a material inducement to his employment.
The stock options have a per share exercise price equal to the fair market value of the underlying shares on the respective date of grant and vest, subject to the respective employee’s continued service with the Company, over a four-year period (
The stock options and RSUs were approved by the Company’s Compensation Committee, which is comprised solely of independent directors, and were granted outside the Company’s equity incentive plan as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
About Carlsmed, Inc.
Carlsmed is a medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond.
Forward Looking Statements
Any statements in this press release about future expectations, plans and prospects and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including such important factors as are set forth under the caption “Risk Factors” in Carlsmed’s Annual Report on Form 10-K on file with the U.S. Securities and Exchange Commission. The forward-looking statements included in this press release represent Carlsmed’s views as of the date of this press release. Carlsmed anticipates that subsequent events and developments will cause its views to change. However, while Carlsmed may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Carlsmed’s views as of any date subsequent to the date of this press release.
Investor Relations
IR@Carlsmed.com
Media
media@Carlsmed.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What are the vesting terms for Carlsmed's executive inducement grants?
The options vest over four years, while the RSUs vest in three equal annual installments, subject to each executive's continued service. Options vest 25% on the first anniversary of the applicable grant date, with the remainder in 12 equal quarterly installments thereafter. RSU vesting begins on the first anniversary of the applicable grant date.